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Abstract In vivo expression of P-glycoprotein in isolated rat 
brain mierovessels is compared with that in vitro in primary 
cultures of brain endothelial cells. More P-glycoprotein is de- 
tected by Western immunoblotting in microvessels than in cul- 
tured endothelium. RT-PCR with isnform-specific primers and 
immunobiotting with a mdrlb-specific antibody reveals only 
mdrla in vivo but both mdrla and mdrlb in vitro. Thus mdrla 
decreases whereas mdrlb increases during culture. P-Glycopro- 
tein activity is evident in vitro, with resistance modulators, e.g. 
verapamil, producing increases in intracenular [3H]vincristine ac- 
cumulation. Endothelial cells cultured from epididymal fat pad 
microvaseulature and aorta contain little or no P-glycoprotein. 
Here, resistance modulators are less effective. 
Key words: P-Glycoprotein isoforms; Rat brain microvessel 
endothelium; Primary cell culture; Blood-brain barrier; 
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The purpose of this study was therefore two-fold: (i) to com- 
pare the amount and nature of P-glycoprotein expressed in 
isolated brain microvessels with that seen in endothelial cells 
derived from these microvessels and maintained in primary 
culture; and (ii) to establish the extent of P-glycoprotein activity 
in the cultured endothelial cells. We have also investigated 
expression in endothelial cells derived from rat epididymal fat 
pad microvasculature and from rat aorta where P-glycoprotein 
has not been reported in vivo [2,3,9]. We demonstrate here that 
there is a correlation in these cultured endothelial cells between 
the level of P-glycoprotein expression and its functional activity 
as judged by chemosensitivity o vincristine and doxorubicin, 
ability to efflux vincristine and sensitivity of this process to 
various resistance modulators. 
2. Materials and methods 
1. Introduction 
P-Glycoprotein is a drug efflux pump important in expelling 
a range of cytotoxic agents from tumour cells thus rendering 
them resistant o anticancer treatment, i.e. multidrug resistant 
(MDR) [1]. This protein is also present in a number of normal 
tissues including vascular endothelial cells lining the capillaries 
that form part of  the blood-brain barrier [2,3,4]. Recent evi- 
dence suggests that it may be important in this situation for 
preventing entry of toxic substances to the brain [5]. 
Several different in vitro systems of brain endothelial cell 
culture have been developed to investigate various aspects of 
blood brain barrier function [6,7,8] including likely access of  
compounds to the brain. It has been shown both in primary 
cultures [9,10,11] and in immortalised cell lines [12,13,14] that 
endothelial cells derived from brain microvessels can express 
P-glycoprotein. However, it has been reported that brain endo- 
thelial cells in culture may lose many of their characteristics 
[15]. Clearly therefore it is important o determine how closely 
structural and functional expression of P-glycoprotein i  brain 
endothelial cells during culture mirrors that seen in vivo in the 
brain microvessels. 
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Abbreviations." BSA, bovine serum albumin; Dil-Ac-LDL, 1,1'-dioc- 
tadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate-labelled 
acetylated low density lipoprotein; DMSO, dimethyl sulfoxide; MDR, 
multidrug resistant; PBS, phosphate-buffered saline; RT-PCR, reverse 
transcription polymerase chain reaction; SDS, sodium dodecyl 
sulphate. 
2.1. Cell &olation and culture 
Each primary culture of brain endothelial cells was grown from 
capillary fragments isolated from the cortical grey matter from the 
brains of 4~5 male Wistar rats 180-200 g in weight according to a 
method previously described [8]. This method includes a preliminary 
digestion of cortical grey matter dissected free of meninges, removal of 
myelin by centrifugation through 22% BSA followed by more pro- 
longed digestion, then separation of individual microvessels from con- 
taminating cells by centrifugation through a Percoll gradient. Mi- 
crovasculature from the epididymal fat pad was isolated by a similar 
method using tissue dissected at the same time. Aortic endothelial cells 
were cultured from aortic rings taken from the same animals. Cells were 
grown in collagen coated culture flasks or multiwell plates in Hams F 10 
medium containing 20% plasma derived serum and 75/lg/ml endothe- 
lial cell growth supplement (both from Adv anced Protein Products, 
West Midlands, UK), 80/lg/ml heparin, 0.5/.tg/ml vitamin C, 2 mM 
L-glutamine, 100 U/mlpenicillin and 100/2g/ml streptomycin. 1 3days 
after isolation of brain microvessels, pindle-shaped cells grow out from 
the original endothelial cell clusters. Other cell types [8] may be found 
in this initial culture, but following the first passage at day 7, few if any 
non-endothelial cells remain. Endothelial cells derived from the epidi- 
dymal fat pad microvasculature and from the aorta are less spindle- 
shaped. Cells were used for drug accumulation studies or for RNA and 
protein analysis after 1-5 passages. To confirm their endothelial nature, 
cells were examined for their ability to take up fluorescence-labelled 
DiI-Ac-LDL (Biogenesis, Bournemouth, UK) following a 4 h exposure 
to a 20/2g/ml solution. 
MDR and parent cell lines used as positive and negative controls 
were cultured as described [16]. These included mouse mammary tu- 
mour cell lines, EMT6/P and the MDR variant, EMT6/ARI.0, which 
is maintained in 1.0/lg/ml doxorubicin and is known to contain only 
the P-glycoprotein isoform, mdrla [16]. Membrane protein of the 
mouse fibrosarcoma line, L0.5, which contains the P-glycoprotein 
isoform, mdrlb (Holmes, personal communication) was supplied by 
Ms. Julie Holmes of MRC Clinical Oncology Unit in Cambridge. 
2.2. Western blot analysis 
Membranes were prepared from isolated brain capillaries or from 
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cultured cells by centrifugation (60,000 x g for 1 h) following cell lysis 
in 1 mM Tris buffer, pH 7.4 containing protease inhibitors (2 ¢tg/ml 
aprotinin, 5/~g/ml leupeptin and 0.08/tg/ml pepstatin). Some samples 
were further subjected to glycosidase digestion, i.e. 25/~g aliquots of 
protein, solubilised in 0.5% SDS at room temperature for 10 min, 
diluted five-fold with 50 mM mannitol, 5mM HEPES, 10 mM Tris, 1% 
Triton, 0.25% fl-mercaptoethanol at pH 7.4 in the presence of protease 
inhibitors as above were subdivided and incubated for 18 h at room 
temperature with or without endoglycosidase F/N-glycosidase F mix- 
ture (Sigma; E 8762) at 2 U/mg protein. Proteins were resolved by SDS 
gel electrophoresis in 7.5% polyacrylamide, electroblotted onto nitro- 
cellulose, the filters probed with anti-P-glycoprotein antibodies, C219 
(CIS UK Ltd., Bucks) or 265lF4 (originally agift from McGuire [16]), 
both at 100 ng/ml in Tris-buffered saline containing 2.5% bovine serum 
albumin and P-glycoprotein visualised using an ECL western blotting 
analysis ystem (Amersham Int.). 
2.3. RT-PCR analysis 
Total cellular RNA was prepared from PBS washed cells by guani- 
dine hydrochloride lysis, phenol/chloroform extraction and ethanol 
precipitation. Single-strand cDNA was made from 1 pg of this RNA 
by reverse transcription using a random hexamer following which frag- 
ments specific to rat mdrla, mdrlb and mdr2 genes were amplified 
through 20 or 30 cycles of 94°C for 1 min, 55°C for 2 min and 72°C 
for 2 min using oligonucleotide primers appropriate to the particular 
isoform, i.e. sense sequence common to all three isoforms, ACAGA- 
AACAGAGGATCGC (bases 1599-1617) and antisense sequences for 
mdrla, CGTCTTGATCATGTGGCC (bases 2032 2015), for mdrlb, 
AGAGGCACCAGTGTCACT (bases 1951-1934) and for mdr2, 
ATGCGTGCTTTCCAGCCA (bases 1981 1964) [17]. As an internal 
control, a sample of each first-strand cDNA was also treated with 
primers able to amplify a 200 base-pair f agment of the rat flz-/d-globu- 
lingene [18]. In some experiments, sets of primers able to amplify either 
a 200 base pair fragment and or a 400 base pair fragment of the rat 
fl-actin gene [19] were used. The PCR products were separated by 
electrophoresis in 2% agarose and visualised by UV in the presence of 
ethidium bromide. 
2.4. Chemosensitivity assay 
The assay used was a modification [20] of that originally described 
by Mosmann. Briefly cells plated in 96-well plates at l03 cells per well 
were grown for 5 days with or without cytotoxic drug. They were then 
incubated for 5 h with 0.5 mg/ml 3-[4,5-dimethylthiazol-2-yl]-2,5- 
diphenyl-tetrazolium (MTT) to allow an insoluble red precipitate to 
form in cells possessing viable mitochondria. The bulk of the medium 
was then removed and the precipitate dissolved by shaking for 10 rain 
in 200/,tl DMSO. The optical densities were read at 540 nm on a Titertek 
Multiskan plate reader and the results expressed asa fraction ofabsorb- 
ance in drug free wells. 
2.5. Drug accumulation studies 
Cells were plated into 12-well plates (for efflux) or 24-well plates (for 
uptake) at a density of 5 x 104 cells/well and left for 5 days to reach near 
confluence. For uptake, cells were pretreated for 30-60 min at 37°C 
with Ham's F10 containing 5 mg/ml BSA and 0.5pg/ml vitamin C with 
or without he resistance modifying drugs, verapamil, quinidine, ta- 
moxifen, cyclosporin A (gift from Dr RR. Twentyman), progesterone, 
forskolin and dideoxyforskolin, before incubation i the presence of 30 
nM [3H]vincristine (5-10 Ci/mmol)(Amersham Int., Bucks., UK)with 
or without drugs. Following 3 washings with ice-cold PBS, the cells 
were lysed with 400 pl of 0.1% SDS and the amount of [3H]vincristine 
accumulated assessed by liquid scintillation counting. Preliminary time 
course experiments established that vincristine accumulation had 
reached equilibrium by 90 min. This single time interval was used in 
subsequent experiments. For efflux, cells were loaded by incubation for 
2 h at 37°C in the Hams/BSA/vitamin C medium containing 30 nM 
[3H]vincristine and 0.33/IM verapamil. After 3 washings with ice-cold 
PBS, cells were then incubated for 90 min in 2 ml of medium alone with 
or without he resistance modifying drugs. The amount of intracellular 
[3H]vincristine remaining at this time was assessed following removal 
of efflux medium and lysis of the cells in 400/.tl of 0.1% SDS by liquid 
scintillation counting. 
To determine the effect of energy depletion on drug accumulation, 
uptake and efflux of [3H]vincristine was investigated using buffer of 
similar ionic composition and pH to Ham's medium with 10 mM 
glucose excluded and 6 mM deoxy-glucose and 10 mM sodium azide 
added to the test wells to reduce ATP levels. 
Unless otherwise stated, all compounds were either standard 
laboratory reagents of analytical grade or from Sigma (Poole, Dorset, 
UK). 
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Fig. 1. lmmunodetection of P-glycoprotein on Western blots of membrane protein from isolated brain microvessels (MV), primary cultured brain 
endothelial cells (BEC), endothelial cells cultured from epididymal tht pad microvasculature (EEC) and cultured aortic endothelial cells (AEC) and 
also from multidrug resistant mouse tumour cell lines, AR1.0 and L 0.5.20 #g aliquots of protein were loaded per well in (a), (f) and BEC in (d) 
and (e); 10 yg were loaded in (c); 5/tg were loaded in (b) and L 0.5 and ARI.0 in (d) and (e). Filters were probed with C219 in (a), (b), (e) and (f) 
and 265/F4 in (c) and (d). Each section, i.e. (a) to (f) is from a separate gel. Arrow denotes position of 170 kDa proteins including lycosylated 
P-glycoproteins. 








Fig. 2. RT-PCR analysis of mdr 1 a, mdr 1 b (upper gel), fl-microglobulin 
and fl-actin (lower gel) expression in RNA samples prepared from 
isolated brain microvessels (lanes 1 and 2), cultured brain endothelial 
cells (lane 3), endothelial cells cultured from epididymal fat pad mi- 
crovasculature (lane 4) and cultured aortic endothelial cells (lane 5). 
PCR products tained with ethidium bromide are visualised under UV. 
DNA size markers from HaelII-digested q~X174-RF DNA are shown 
in lane <>. 
3. Results 
P-Glycoprotein expression i membranes prepared from iso- 
lated brain microvessels and from cultured brain endothelial 
cells was analysed on Western blots using monoclonal anti- 
body, C219. With this antibody, P-glycoprotein was detected 
in membranes of the isolated microvessels (MV) (Fig. la and 
b) in amounts comparable to those found in MDR mouse 
tumour cell lines, EMT6/AR1.0 [16] and L 0.5. A moderate 
amount of P-glycoprotein was observed in membranes ofendo- 
thelial cells cultured from the brain microvessels (BEC) (Fig. 
1 a, b, e and f) and this was maintained through several passages 
(not shown). The monoclonal antibody, 265/F4, that detects the 
protein product of the mouse mdrlb gene but not that of the 
mdrla gene [16] did not recognise the P-glycoprotein i  the 
brain microvessel membranes (MV) (Fig. lc) or in the AR1.0 
cells (Fig. ld) but did recognise the P-glycoprotein present in 
the primary cultured brain endothelial cells and in the L 0.5 
cells (Fig lc and d). Low amounts of P-glycoprotein were found 
in endothelial cells cultured from the epididymal fat pad mi- 
crovasculature (EEC) (Fig. lf) and little if any in endothelial 
cells cultured from the aorta (AEC) (Fig. l f). 
The P-glycoprotein the cultured brain endothelial cells was 
of slightly lower molecular weight (150-160 kDa) than that 
found in the isolated brain microvessels (170 kDa) (Fig. la and 
b). Endoglycosidase treatment reduced the apparent molecular 
weights in both cell preparations to around 130-140 kDa (gels 
not shown). 
RT-PCR analysis was undertaken to determine the isoform 
of P-glycoprotein expressed. With primers specific for the 
mdrla gene (Fig. 2, upper gel), a band corresponding to the 
expected size (433 bp) was obtained from RNA prepared from 
isolated brain microvessels (lanes l and 2) and from endothelial 
cells cultured from these microvessels (lane 3). Whether ampli- 
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fication was done through 20 or 30 cycles, there was no obvious 
difference in the level of expression between the different RNA 
preparations. With primers pecific for the mdrlb gene (Fig. 2, 
upper gel), a fragment corresponding to the expected size (352 
bp) was amplified from RNA prepared from cultured cells of 
brain endothelium and epididymal fat pad microvasculature 
(lane 4) but not from isolated brain microvessels or from aortic 
endothelial cells (lane 5). There was little evidence of mdr2 
expression i  any of the samples analysed (gels not shown). To 
check the integrity of the RNA and efficiency of the RT-PCR, 
primers pecific for rat ,B-p-globulin were used as internal con- 
trols on samples of first strand cDNA. A band of the expected 
size (200 bp) was obtained with RNA from isolated brain mi- 
crovessels and from cultured cells of brain endothelium and 
epididymal fat pad microvasculature but not from aortic endo- 
thelial cells (Fig. 2, lower gel). Rat fl-actin primers used as an 
alternative control produced fragments of the expected sizes in 
all samples of RNA from each endothelial cell type (Fig. 2, 
lower gel). Thus aortic endothelial cells apparently do not ex- 
press the fl-p-globulin gene during culture. 
The effect of the cytotoxic agents, vincristine and doxorubi- 
cin, on viability of the endothelial cells in culture was examined. 
Endothelial cells from the brain microvessels (BEC) were less 
susceptible to cytotoxic drug treatment than those from the 
epididymal fat pad microvasculature (EEC) with ECs0 values 
(mean + S.E.M. from 4-6 experiments) in mg/ml for vincristine 
of 0.27 + 0.027 (BEC) vs. 0.037 + 0.008 (EEC) and for doxoru- 
bicin of 0.44 + 0.051 (BEC) vs. 0.095 (EEC). The resistance 
modifying agent, verapamil, increased the sensitivity of the 
brain endothelial cells to vincristine, the +isomer being equally 
as effective as the racemic mixture with regard to its chemosen- 
sitising action (shift in ECs0 from 0.22 tg/ml to 0.03, 0.013 and 
0.005 pg/ml with 0.3, 1 and 10 tM racemic verapamil and to 
0.04, 0.014 and 0.006 pg/ml with 0.3, 1 and 10 tM dex-vera- 
pamil, values being the mean of results from two separate 
experiments). 
Movement of [3H]vincristine into and out of the cultured 
endothelial cells was monitored as uptake during exposure to 
30 nM vincristine and as efflux after preloading of cells by 
exposure to 30 nM vincristine. More drug was taken up and 
less drug effluxed in 90 min from endothelial cells derived from 
the epididymal fat pad microvasculature (EEC) and from the 
aorta (AEC) than in cells derived from the brain microvessels 
(BEC): uptake values in fmol/105 cells (mean of results from 4-6 
experiments + S.E.M.) of 32.5 + 8.5 (AEC), 18.6 + 3.1 (EEC) 
and 9.9 + 1.2 (BEC) and efflux values in terms of proportions 
remaining after 90 min (mean + S.E.M.) of 0.93 + 0.05 (AEC), 
0.29 + 0.02 (EEC) and 0.18 + 0.02 (BEC). 
Both uptake and efflux were also investigated in the presence 
of various resistance modifiers including verapamil (10 tiM), 
quinidine (10 tiM), tamoxifen (50 tM)  and cyclosporin A (2.5 
tg/ml). At the concentrations given, these modifying agents 
increased rug accumulation very little in aortic endothelial 
cells (AEC) (Fig. 3c), to a small extent in epididymal endothelial 
cells (EEC) (Fig. 3b) but to a significant degree in brain endo- 
thelial cells (BEC) (Fig. 3a). Similar increases in brain endothe- 
lial cell drug accumulation were observed in the presence of 
forskolin (40 tiM), dideoxyforskolin (40 pM) and progesterone 
(50 tM)  (Fig. 3a). The effects of verapamil and progesterone 
were dose dependent (Fig. 3d). 
Following energy depletion, there was a significant increase 
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Fig. 3. Effects of energy depletion (-ATP) and of resistance modifiers, 10 ¢tM verapamil (VER), 10,uM quinidine (QUIN), 10/zM tamoxifen (TAM) 
and 2.5/lg/ml cyclosporin A (CSA) on drug accumulation i  (a) brain endothelial cells (BEC), (b) endothelial cells of epididymal fat pad microvas- 
culature (EEC) and (c) aortic endothelial cells (AEC) following 90 min exposure to 30 nM [3H]vincristine. (d)Effects of different concentrations of 
verapamil and progesterone onaccumulation in brain endothelial cells. Values hown are the mean + S.E.M. of results from 3 ~, separate experiments, 
triplicate determinations being obtained from each. 
in drug accumulation i  the brain endothelial cells (BEC) (Fig. 
3a). A small but insignificant increase also was evident in the 
aortic endothelial cells (AEC) in the uptake but not the efflux 
experiments. 
4. Discussion 
The present study compares the amount and isoform of 
P-glycoprotein expressed inbrain microvessels in vivo with that 
in primary cultures of cells grown in vitro from these mi- 
crovessels. The levels in the isolated vessels are comparable 
with those detectable in the mouse MDR cell lines, L 0.5, 
maintained in 0.5 ¢tg/ml vindesine and EMT6/AR1.0 main- 
tained in 1/tg/ml doxorubicin [16]. Lower levels are present in 
the endothelial cells cultured from the microvessels. There is 
thus significant loss of expression during cell culture. 
Three isoforms of P-glycoprotein have been identified in 
rodent tissues, mdrla, mdrlb and mdr2 [21]. The antibody, 
C219, used in this study recognises a highly conserved region 
of P-glycoprotein [22] so it cannot distinguish between the 
different isoforms. The other antibody, 265/F4, recognises only 
the mdrlb isoform [16] and so can detect differences in isoform 
expression. This antibody revealed that mdrlb is not present 
in vivo in the brain microvessels but appears in the brain endo- 
thelial cells during culture. This was confirmed by RT-PCR 
analysis using primers pecific for the mdrla and mdrl b genes. 
These observations are in agreement with previous reports in 
both rat and mouse that mdrla is the only isoform found in 
vivo in brain capillaries [23]. Indeed, ablation of the mdr I a gene 
alone in mice leads to altered pharmacokinetics of certain cyto- 
toxic drugs, allowing much higher levels to enter the brain [5]. 
An additional protein, 190 kDa in size has been detected by 
others using C219 in membranes prepared from rat brain cap- 
illaries [24]. No such protein was observed in this present study. 
The C219 antibody used in that investigation was, however, 
obtained from a source different from that used here and it is 
possible (Beaulieu, personal communication) that it detects ep- 
itopes in addition to the highly conserved sequence already 
mapped [22]. 
Thus mdrla decreases whereas mdrlb increases during cul- 
ture of rat brain endothelial cells. Similar results have been 
obtained by other workers (Bergmann and Roux, personal 
communication). Various factors including hormones and ad- 
verse environmental stresses, as may occur during cell culture, 
can affect mdr gene expression. Isolated rat hepatocytes for 
example show dramatic increases in P-glycoprotein expression 
over the course of 2-4 days in culture [25]. This expression 
which appears to be negatively regulated by a protein factor [26] 
involves upregulation of the mdrlb isoform with concomitant 
down-regulation f the mdr 1 a isoform [27]. Culture conditions 
including the presence of serum and the nature of the substra- 
tum seem to be important in altering expression i hepatocytes 
and may well play a part in modifying P-glycoprotein expres- 
sion in brain endothelial cells. 
There was no detectable expression of mdr2 RNA in any of 
the endothelial cell preparations. This isoform, expressed pri- 
marily on bile canalicular membranes of hepatocytes [28], is 
associated with normal bile secretion but is not involved with 
decreased accumulation f cytotoxic drugs and increased rug 
resistance [29]. 
In addition to changes in isoform of the P-glycoprotein ex- 
pressed uring culture, there appeared to be alterations also in 
glycosylation with fewer carbohydrate moieties linked to the 
protein in vitro. There are known to be variations in glycosyl- 
ation of P-glycoproteins derived from different mouse tissues 
[21] but whether these reflect differences in functional activity 
is unclear. Though complete N-glycosylation of the human 
MDR1 gene product is not thought essential for drug binding 
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[30] or transport, N-glycosylation may affect drug transport 
indirectly by influencing routing and stability of P-glycoprotein 
[311. 
Expression of P-glycoprotein is not confined to microvessels 
in the brain but has been observed also on microvasculature in 
other tissues, e.g. lung and testis [3]. In the present study, a 
small amount of P-glycoprotein was detected in endothelial 
cells grown from the microvasculature of the epididymal fat 
pad. Too few cells could be harvested uring the initial isolation 
to provide sufficient material for analysis so it is not clear 
whether P-glycoprotein is normally expressed here in vivo or 
whether it arises during in vitro culture. 
These cells were originally cultured as putative P-glycopro- 
tein-negative endothelial cell controls for the functional studies. 
The endothelial cells derived from the aorta proved to be more 
appropriate for this purpose since these cells lack detectable 
P-glycoprotein. 
Functional activity of P-glycoprotein as assessed by drug 
sensitivity, drug accumulation and the sensitivity of these para- 
meters to resistance modulators was not tested in the isolated 
brain microvessels owing to the small amount of material avail- 
able but was investigated in the cultured endothelial cells. In 
these cells, there was a clear correlation between the degree of 
functional activity and the level of P-glycoprotein expression 
with significant activity in the brain endothelium and none in 
the aortic endothelium. 
The alterations een in this study in the isoform of P- 
glycoprotein expressed uring cell culture may be of signifi- 
cance with regard to the transport capability of the protein in 
vitro. The protein products of the mdr la  and mdr lb  genes have 
overlapping but not identical capacities for transport of differ- 
ent drugs [32] and their sensitivities to modulators are also 
different. Phosphorylation is an additional factor that may reg- 
ulate P-glycoprotein activity and requires investigation i both 
in vivo and in vitro situations. The possibility of changes oc- 
curing to P-glycoprotein during cell culture should be born in 
mind when in vitro models are used to assess the capability of 
various lipophilic agents to cross the blood-brain barrier. 
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